How many 8-K filings has Cns Pharmaceuticals, Inc. filed?

Cns Pharmaceuticals, Inc. (CNSP) has 33 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Cns Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Cns Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Cns Pharmaceuticals, Inc. (CNSP) — 8-K Filings

All 8-K filings from Cns Pharmaceuticals, Inc.. Browse 33 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (33)

8-K Filing — May 4, 2026
CNS Pharmaceuticals Files 8-K on Officer Changes and Financials — Dec 17, 2025 Risk: medium
On December 16, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing also includes
8-K Filing — Nov 21, 2025
CNS Pharmaceuticals Closes $1.5M Private Placement — Jul 22, 2025 Risk: medium
On July 17, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the closing of a private placement of its co
CNS Pharmaceuticals Files 8-K Report — Jul 15, 2025 Risk: low
On July 15, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. N
CNS Pharmaceuticals Files 8-K Report — Apr 9, 2025 Risk: low
On April 9, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop So
CNS Pharmaceuticals Files 8-K: Other Events & Financials — Mar 20, 2025 Risk: low
On March 20, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
CNS Pharmaceuticals Files 8-K: Security Holder Rights & Exhibits — Feb 21, 2025 Risk: low
On February 19, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and other events. The filing also
CNS Pharmaceuticals Closes $1.5M Private Placement — Jan 3, 2025 Risk: medium
On January 3, 2025, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several events. The company announced the closing of a private placement of its comm
CNS Pharmaceuticals Files Current Report — Dec 11, 2024 Risk: low
On December 11, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's current report status and financial statements
CNS Pharmaceuticals Files 8-K on Shareholder Vote Matters — Dec 3, 2024 Risk: low
On November 26, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report to disclose matters submitted to a vote of its security holders. The filing indicates a shar
CNS Pharmaceuticals Appoints New Chief Medical Officer — Nov 1, 2024 Risk: medium
On October 30, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John "Jack" W. Smith as Chief Medical Officer. Dr. Smith brings extensive experi
CNS Pharmaceuticals Files 8-K for Material Definitive Agreement — Oct 24, 2024 Risk: medium
On October 23, 2024, CNS Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company, incorporated in Nevada with its principal executive of
CNS Pharmaceuticals Files 8-K — Oct 23, 2024 Risk: low
On October 23, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 2100 West Loop
CNS Pharmaceuticals Faces Nasdaq Listing Rule Non-Compliance — Sep 18, 2024 Risk: high
CNS Pharmaceuticals, Inc. received a notification on September 12, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capita
CNS Pharmaceuticals Faces Delisting Notice — Sep 12, 2024 Risk: high
CNS Pharmaceuticals, Inc. filed an 8-K on September 10, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is bas
CNS Pharmaceuticals Appoints New Chief Medical Officer — Aug 7, 2024 Risk: medium
On August 6, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John A. McCarthy as Chief Medical Officer. Dr. McCarthy brings extensive experienc
CNS Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Jul 30, 2024 Risk: medium
On July 29, 2024, CNS Pharmaceuticals, Inc. entered into a material definitive agreement, likely related to its operations in the pharmaceutical preparations in
CNS Pharmaceuticals Files Material Definitive Agreement — Jul 26, 2024 Risk: medium
On July 26, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exh
CNS Pharmaceuticals Faces Nasdaq Delisting Warning — Jul 24, 2024 Risk: high
CNS Pharmaceuticals, Inc. received a notice on July 19, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Nasdaq
CNS Pharmaceuticals Appoints New Chief Medical Officer — Jul 9, 2024 Risk: medium
On July 5, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John W. Semple as Chief Medical Officer. Dr. Semple brings extensive experience in n
CNS Pharmaceuticals Raises $1M in Stock Sale — Jul 3, 2024 Risk: medium
On July 3, 2024, CNS Pharmaceuticals, Inc. announced an entry into a material definitive agreement, specifically a Securities Purchase Agreement with an accredi
CNS Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Jun 26, 2024 Risk: medium
On June 26, 2024, CNS Pharmaceuticals, Inc. announced an entry into a material definitive agreement. The company also reported on unregistered sales of equity s
CNS Pharmaceuticals Closes $1.5M Stock Sale — Jun 14, 2024 Risk: medium
On June 14, 2024, CNS Pharmaceuticals, Inc. entered into a Material Definitive Agreement, specifically a Securities Purchase Agreement, with an investor. This a
CNS Pharmaceuticals Closes $1.5M Private Placement — Jun 5, 2024 Risk: medium
On June 3, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the closing of a private placement of its com
CNS Pharmaceuticals Files 8-K — May 16, 2024 Risk: low
CNS Pharmaceuticals, Inc. filed an 8-K on May 16, 2024, to report on its results of operations and financial condition, as well as to file financial statements
CNS Pharmaceuticals Appoints New Chief Medical Officer — May 7, 2024 Risk: medium
On May 6, 2024, CNS Pharmaceuticals, Inc. announced the appointment of Dr. John M. McCarthy as Chief Medical Officer. Dr. McCarthy brings extensive experience i
CNS Pharmaceuticals Announces Board Changes and Officer Appointments — May 3, 2024 Risk: medium
On April 30, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report detailing several key events. These include the election of Dr. John "Jack" Roberts as Chairman
CNS Pharmaceuticals Files 8-K — Apr 15, 2024 Risk: low
On April 9, 2024, CNS Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD dis
CNS Pharma Faces Delisting Notice, Announces Officer Changes — Feb 27, 2024 Risk: high
CNS Pharmaceuticals, Inc. filed an 8-K on February 27, 2024, reporting events that occurred on February 21, 2024. The filing indicates the company received a no
CNS Pharmaceuticals to Delist from Nasdaq, Move to OTCQB — Feb 21, 2024 Risk: high
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) received a delisting notice from Nasdaq on February 14, 2024, due to its failure to maintain the minimum bid price of $
CNS Pharma Enters Material Agreement, Signals Leadership Changes — Feb 2, 2024
CNS Pharmaceuticals, Inc. (CNSP) entered into a material definitive agreement on January 29, 2024, with an unnamed party, which could significantly impact its o
CNS Pharma Reports Executive/Director Changes, Comp Arrangements — Jan 23, 2024
CNS Pharmaceuticals, Inc. filed an 8-K on January 23, 2024, reporting an event that occurred on January 17, 2024. The filing indicates changes related to the 'D

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX